New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
07:15 EDTPCYCPharmacyclics price target raised to $96 from $83 at Piper Jaffray
Piper Jaffray said Pharmacyclics confirmed the filing for ibrutinib in Mantle Cell Lymphoma, or MCL, by year end, which places the launch one year ahead of Street expectations. The firm raised its price target for shares and keeps an Overweight rating on the name.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
08:05 EDTPCYCPharmacyclics files supplemental new drug application for Imbruvica
Pharmacyclics announced that it has submitted a supplemental New Drug Application to the FDA, based on data from the randomized, multi-center, open-label Phase III Resonatetm study, PCYC-1112, a head-to-head comparison of single agent Imbruvicatm versus ofatumumab in 391 patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, who had received at least one prior therapy. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use